BBIO - BridgeBio Pharma - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BBIO is currently covered by 13 analysts with an average price target of $64.58. This is a potential upside of $19.72 (43.96%) from yesterday's end of day stock price of $44.86.

BridgeBio Pharma's activity chart (see below) currently has 105 price targets and 125 ratings on display. The stock rating distribution of BBIO is 98.31% BUY and 1.69% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 61.47% with an average time for these price targets to be met of 245.07 days.

Highest price target for BBIO is $95, Lowest price target is $46, average price target is $54.23.

Most recent stock forecast was given by GEOFF MEACHAM from BAML on 25-Jun-2025. First documented stock forecast 22-Jul-2019.

Currently out of the existing stock ratings of BBIO, 58 are a BUY (98.31%), 1 are a HOLD (1.69%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$54

$9.14 (20.37%)

$45

4 days ago
(25-Jun-2025)

5/7 (71.43%)

$9.62 (21.68%)

191

Buy

$56

$11.14 (24.83%)

$53

20 days ago
(09-Jun-2025)

16/25 (64%)

$16.97 (43.48%)

310

Buy

$72

$27.14 (60.50%)

$54

1 months 30 days ago
(30-Apr-2025)

2/6 (33.33%)

$33.64 (87.70%)

334

Buy

$55

$10.14 (22.60%)

$52

1 months 30 days ago
(30-Apr-2025)

5/8 (62.5%)

$16.64 (43.38%)

227

Buy

$50

$5.14 (11.46%)

$43

3 months 5 days ago
(24-Mar-2025)

12/14 (85.71%)

$12.78 (34.34%)

179

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BBIO (BridgeBio Pharma) average time for price targets to be met?

On average it took 245.07 days on average for the stock forecasts to be realized with a an average price target met ratio 61.47

Which analyst has the current highest performing score on BBIO (BridgeBio Pharma) with a proven track record?

TYLER VAN BUREN

Which analyst has the most public recommendations on BBIO (BridgeBio Pharma)?

Tyler Van Buren works at TD COWEN and has 5 price targets and 3 ratings on BBIO

Which analyst is the currently most bullish on BBIO (BridgeBio Pharma)?

Josh Schimmer with highest potential upside - $50.14

Which analyst is the currently most reserved on BBIO (BridgeBio Pharma)?

Eun Yang with lowest potential downside - -$20.86

BridgeBio Pharma in the News

High Growth Tech Stocks In The US Market May 2025

Over the last 7 days, the United States market has risen by 2.7%, contributing to a 9.6% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive market trends....

BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations

BridgeBio Pharma (NASDAQ:BBIO) First Quarter 2025 Results Key Financial Results Revenue: US$116.6m (down 45% from 1Q 2024). Net loss: US$167.4m (loss widened by 375% from 1Q 2024). US$0.88 loss per share (further deteriorated from US$0.20 loss in 1Q 2024). We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6%...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?